School of Medicine
Showing 701-720 of 769 Results
-
Andre Kumar MD, MEd
Clinical Associate Professor, Medicine
BioDr. Andre Kumar is a Clinical Associate Professor in the Stanford Division of Hospital Medicine with a passion for improving patient care through Point-of-Care Ultrasound (POCUS), clinical research, and education. He earned his MD from Tulane University and completed his residency, chief residency, and a Master's in Education at Stanford University.
As a passionate educator and researcher, Dr. Kumar has completed three randomized trials on POCUS and its impact on patient care. He continues to conduct research and teach POCUS on a local and national level, and is committed to improving the science and education that underlie the next generation of diagnostic tools. He is the lead investigator for a multicenter trial related to ultrasound and COVID-19. Dr. Kumar was also an investigator for the ACTT and ACTIV trials for COVID-19, which brought the first COVID-19 therapeutics to patients nationwide. Currently, he serves as the Co-PI at Stanford for the National Institutes of Health RECOVER trial, a $1 billion effort to understand the long-term effects of COVID-19 on patients.
Dr. Kumar has held numerous leadership positions that reflect his commitment to advancing medical education and clinical practice. He is the Director of the Clinical Research Unit for the Division of Hospital Medicine and the Director of the Rathmann Fellowship in Medical Education at Stanford University School of Medicine. In the School of Medicine, he serves as the Co-Director of Clinical Reasoning, Associate Course Director for the Practice of Medicine course. Dr. Kumar is also the Director of the Jane A. Stanford Scholars Program and Co-Founder and Director of the ASPIRE Grant Program in the Stanford Division of Hospital Medicine.
His contributions to medical education have been recognized with several awards, including the Lawrence H. Mathers Award for Exceptional Commitment to Teaching in 2023, the Henry J. Kaiser Foundation Award for Excellence in Clinical Teaching (2018, 2022), and the David A. Rytand Clinical Teaching Award (2018, 2022). Dr. Kumar has contributed to the creation of educational content, including videos for the Stanford Medicine 25 series that cover various aspects of POCUS.
List of publications: https://bit.ly/3eop95i
ClinicalTrials.Gov registration:
https://bit.ly/2TizOmD
https://bit.ly/2zeNBjJ
Media:
https://shorturl.at/rNU46
https://stanfordmedicine.box.com/s/jm3544zdwpihj6bstcv72x76zq9nuzbq
https://bit.ly/33MZa0O
https://bit.ly/3t8HE2u
https://wb.md/2zfjY1N -
Manoj Kumar
Postdoctoral Scholar, Radiology
Current Research and Scholarly InterestsI work on imaging-guided therapy using PET and MR imaging approaches. My academic training and background is in molecular imaging. During my doctoral training, I developed and validated a PET imaging approach for evaluating endocrine therapy responses in advanced breast cancer. My current research focuses on imaging tumor immune markers and responses to cancer immunotherapy. The goal is to develop new imaging toolboxes to monitor and guide treatment. Specifically, I employ antibodies, nanoparticles, and reporter genes for imaging and combinations of therapies to modulate and restore the body's suppressed immune functions against cancer cells. This is being done in collaboration with teams of researchers in early clinical development and teams in clinical practice.
-
Parth I Kumar
Affiliate, Department Funds
Fellow in Medicine - Med/NephrologyBioParth Kumar is a fellow in the Stanford University Nephrology Fellowship Program. Dr. Kumar holds a B.A. in Molecular and Cell Biology from UC Berkeley and an M.D. with Distinction from UCSF School of Medicine. He completed his Internal Medicine Residency at UC Irvine, where he was recognized as the Intern Teacher of the Year in 2022. Dr. Kumar's research interests span health care innovation and translational medicine, such as integrating 3D printing into clinical settings to aid patient education, evaluating novel medical devices. His past work includes the study "Evaluating the use of Radioactive Analogs of Doxorubicin for Quantifying ChemoFilter binding and Whole Body PET/MRI Biodistribution," leading to him being recognized as one of the JVIR Editor's Honorees: Distinguished Laboratory Investigations in 2022.
-
Karteek Kunala
Research Engineer, Ophthalmology Research/Clinical Trials
BioMy current interests are in development of design and instrumentation of pre-clinical vision devices, to conduct non-invasive in vivo retinal imaging. I studied Physics with a concentration in optics during my time at University of Hyderabad, India and received a bachelors and masters degree in 2014. I then moved to USA to continue working in the field of optics at University of North Carolina at Charlotte to pursue my PhD, working on nanofabrication of broadband anti-reflective structures. My interest in vision science started with my job at University of Rochester as a research scientist, where I was involved in developing optical imaging tools using adaptive optics to study retinal diseases. My work was focused on development of fluorescence lifetime imaging techniques in humans and two photon fluorescence microscopy in mouse.
-
Anshul Kundaje
Associate Professor of Genetics and of Computer Science
Current Research and Scholarly InterestsWe develop statistical and machine learning frameworks to learn predictive, dynamic and causal models of gene regulation from heterogeneous functional genomics data.
-
Christian Kunder
Clinical Associate Professor, Pathology
Current Research and Scholarly InterestsMy main interest is in understanding the biology of human neoplasms, using traditional histopathology, molecular genetic techniques, and other modalities. In particular, I am interested in soft tissue and genitourinary neoplasms, especially prostate cancer.
I am also interested in the classification and nomenclature of neoplasms and in practical research that helps us refine these, using a variety of techniques but still principally guided by histopathology.
I also work on developing next generation sequencing-based tests for genotyping tumors and in expanding the scope of this testing with the goal of identifying patients eligible for novel targeting therapies.
